Cargando…
A phase II study of perioperative pembrolizumab plus mFOLFOX in patients with potentially resectable esophagus, gastroesophageal junction (GEJ), and stomach adenocarcinoma
BACKGROUND: Perioperative chemotherapy/chemoradiation is standard in esophageal/gastric/gastroesophageal junction (GEJ) adenocarcinoma, immune checkpoint inhibitors (ICI) effect in setting of metastatic and postoperatively. This study is to assess ICI + chemotherapy perioperatively. METHODS: Patient...
Autores principales: | Sun, Weijing, Veeramachaneni, Nirmal, Al‐Rajabi, Raed, Madan, Rashna, Kasi, Anup, Al‐Kasspooles, Mazin, Baranda, Joaquina, Saeed, Anwaar, Phadnis, Milind A., Godwin, Andrew K., Olyaee, Mojtaba, Streeter, Natalie, Nagji, Alykhan, Dai, Junqiang, Williamson, Stephen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10469814/ https://www.ncbi.nlm.nih.gov/pubmed/37326317 http://dx.doi.org/10.1002/cam4.6263 |
Ejemplares similares
-
Total Neoadjuvant Therapy vs Standard Therapy in Locally Advanced Rectal Cancer: A Systematic Review and Meta-analysis
por: Kasi, Anup, et al.
Publicado: (2020) -
Cabozantinib plus durvalumab in advanced gastroesophageal cancer and other gastrointestinal malignancies: Phase Ib CAMILLA trial results
por: Saeed, Anwaar, et al.
Publicado: (2023) -
Association of Neutrophil, Platelet, and Lymphocyte Ratios with the Prognosis in Unresectable and Metastatic Pancreatic Cancer
por: Allen, Jessica, et al.
Publicado: (2020) -
Phase III Study to Evaluate Efficacy and Safety of Andecaliximab With mFOLFOX6 as First-Line Treatment in Patients With Advanced Gastric or GEJ Adenocarcinoma (GAMMA-1)
por: Shah, Manish A., et al.
Publicado: (2021) -
Cediranib with mFOLFOX6 vs bevacizumab with mFOLFOX6 in previously treated metastatic colorectal cancer
por: Cunningham, D, et al.
Publicado: (2013)